1
|
Miran I, Scherer D, Ostyn P, Mazouni C, Drusch F, Bernard M, Louvet E, Adam J, Mathieu MC, Haffa M, Antignac JP, Le Bizec B, Vielh P, Dessen P, Perdry H, Delaloge S, Feunteun J. Adipose Tissue Properties in Tumor-Bearing Breasts. Front Oncol 2020; 10:1506. [PMID: 32974182 PMCID: PMC7472783 DOI: 10.3389/fonc.2020.01506] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Accepted: 07/14/2020] [Indexed: 12/11/2022] Open
Abstract
The tissue stroma plays a major role in tumors' natural history. Most programs for tumor progression are not activated as cell-autonomous processes but under the conditions of cross-talks between tumor and stroma. Adipose tissue is a major component of breast stroma. This study compares adipose tissues in tumor-bearing breasts to those in tumor-free breasts with the intention of defining a signature that could translate into markers of cancer risk. In tumor-bearing breasts, we sampled adipose tissues adjacent to, or distant from the tumor. Parameters studied included: adipocytes size and density, immune cell infiltration, vascularization, secretome and gene expression. Adipose tissues from tumor-bearing breasts, whether adjacent to or distant from the tumor, do not differ from each other by any of these parameters. By contrast, adipose tissues from tumor-bearing breasts have the capacity to secrete twice as much interleukin 8 (IL-8) than those from tumor-free breasts and differentially express a set of 137 genes of which a significant fraction belongs to inflammation, integrin and wnt signaling pathways. These observations show that adipose tissues from tumor-bearing breasts have a distinct physiological status from those from tumor-free breasts. We propose that this constitutive status contributes as a non-cell autonomous process to determine permissiveness for tumor growth.
Collapse
Affiliation(s)
- Isabelle Miran
- Translational Research Lab, INSERM U981, Université Paris-Saclay, Villejuif, France
| | - Dominique Scherer
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.,Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - Pauline Ostyn
- UMR 9019 Genome Integrity and Cancers, Université Paris-Saclay, Villejuif, France
| | - Chafika Mazouni
- Breast Cancer Group, Université Paris-Saclay, Villejuif, France
| | - Françoise Drusch
- Biology and Pathology Department, Université Paris-Saclay, Villejuif, France
| | - Marine Bernard
- Biology and Pathology Department, Université Paris-Saclay, Villejuif, France
| | - Emilie Louvet
- Biology and Pathology Department, Université Paris-Saclay, Villejuif, France
| | - Julien Adam
- Biology and Pathology Department, Université Paris-Saclay, Villejuif, France
| | - Marie-Christine Mathieu
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), UMR 1329 Oniris-INRA, Nantes, France
| | - Mariam Haffa
- Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.,Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jean-Philippe Antignac
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), UMR 1329 Oniris-INRA, Nantes, France
| | - Bruno Le Bizec
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), UMR 1329 Oniris-INRA, Nantes, France
| | - Philippe Vielh
- Biology and Pathology Department, Université Paris-Saclay, Villejuif, France
| | - Philippe Dessen
- Bioinformatics Core Facility, Université Paris-Saclay, Villejuif, France
| | - Hervé Perdry
- INSERM U669 - Equipe GGS Génomique & Génétique Statistique, Villejuif, France
| | | | - Jean Feunteun
- UMR 9019 Genome Integrity and Cancers, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
2
|
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin MP, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 2020; 31:377-386. [PMID: 32067679 DOI: 10.1016/j.annonc.2019.11.006] [Citation(s) in RCA: 139] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 10/15/2019] [Accepted: 11/04/2019] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug family in the treatment landscape. PATIENTS AND METHODS A total of 649 patients with mBC from the SAFIR02 trial (NCT02299999), with available mutational profiles were selected for outcome analysis. PIK3CA mutations were prospectively determined by next-generation sequencing on metastatic samples. The mutational landscape of PIK3CA-mutated mBC was assessed by whole-exome sequencing (n = 617). Finally, the prognostic value of PIK3CA mutations during chemotherapy was assessed in plasma samples (n = 44) by next-generation sequencing and digital PCR. RESULTS Some 28% (104/364) of HR+/Her2- tumors and 10% (27/255) of triple-negative breast cancer (TNBC) presented a PIK3CA mutation (P < 0.001). PIK3CA-mutated HR+/Her2- mBC was less sensitive to chemotherapy [adjusted odds ratio: 0.40; 95% confidence interval (0.22-0.71); P = 0.002], and presented a worse overall survival (OS) compared with PIK3CA wild-type [adjusted hazard ratio: 1.44; 95% confidence interval (1.02-2.03); P = 0.04]. PIK3CA-mutated HR+/Her2- mBC was enriched in MAP3K1 mutations (15% versus 5%, P = 0.0005). In metastatic TNBC (mTNBC), the median OS in patients with PIK3CA mutation was 24 versus 14 months for PIK3CA wild-type (P = 0.03). We further looked at the distribution of PIK3CA mutation in mTNBC according to HR expression on the primary tumor. Some 6% (9/138) of patients without HR expression on the primary and 36% (14/39) of patients with HR+ on the primary presented PIK3CA mutation (P < 0.001). The level of residual PIK3CA mutations in plasma after one to three cycles of chemotherapy was associated with a poor OS [continuous variable, hazard ratio: 1.03, 95% confidence interval (1.01-1.05), P = 0.007]. CONCLUSION PIK3CA-mutated HR+/Her2- mBC patients present a poor outcome and resistance to chemotherapy. Patients with PIK3CA-mutated TNBC present a better OS. This could be explained by an enrichment of PIK3CA mutations in luminal BC which lost HR expression in the metastatic setting. TRIAL REGISTRATION SAFIR02 trial: NCT02299999.
Collapse
Affiliation(s)
- F Mosele
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - B Stefanovska
- INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France
| | - A Lusque
- Institut Claudius Regaud, IUCT-O, Toulouse, France
| | - A Tran Dien
- Bioinformatics Platform, Gustave Roussy, Villejuif, France
| | - I Garberis
- INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; Paris-Saclay University, Paris, France
| | - N Droin
- Genomic Core Facility UMS AMMICA Gustave Roussy, Villejuif, France
| | - C Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris, France; INSERM U900, Saint-Cloud, France; Paris-Saclay University, Paris, France
| | - M-P Sablin
- Department of Medical Oncology, Institut Curie, Paris, France
| | - L Lacroix
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France; Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - D Enrico
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - I Miran
- Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - C Jovelet
- Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - I Bièche
- Department of Genetics, Institut Curie, Paris, France; INSERM U1016, Paris Descartes University, Paris, France
| | - J-C Soria
- University of Paris-Sud, Orsay, France
| | - F Bertucci
- CRCM, Predictive Oncology team, Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Marseille, France
| | - H Bonnefoi
- Department of Medical Oncology, Institut Bergonie, Bordeaux, France
| | - M Campone
- Department of Medical Oncology, Institut of Cancerology Ouest, Nantes, France
| | - F Dalenc
- Institut Claudius Regaud, IUCT-O, Toulouse, France
| | - T Bachelot
- Department of Medical Oncology, Center Leon Berard, Lyon, France
| | - A Jacquet
- Precision Medicine Group, UNICANCER, Paris, France
| | - M Jimenez
- Precision Medicine Group, UNICANCER, Paris, France
| | - F André
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; University of Paris-Sud, Orsay, France.
| |
Collapse
|
3
|
Mosele F, Lusque A, Tran Dien A, Droin N, Le Tourneau C, Sablin M, Lacroix L, Miran I, Jovelet C, Bieche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Detection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. Int J Cancer 2019; 145:3163-3172. [PMID: 31107542 DOI: 10.1002/ijc.32417] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 04/09/2019] [Accepted: 04/17/2019] [Indexed: 01/07/2023]
Abstract
We examined whether 66 germline single-nucleotide polymorphisms (SNPs) in 10 candidate genes would predict clinical outcome in 316 patients with resectable locally advanced rectal cancer (LARC) enrolled in the ACCORD-12 phase III trial who were randomly treated with preoperative radiotherapy plus capecitabine (CAP45; n = 155) or dose-intensified radiotherapy plus capecitabine and oxaliplatin (CAPOX50; n = 161). The primary endpoint was tumor response according to the Dworak score. Multivariate logistic regression models adjusted on treatment arm and T stage determined the SNPs prognostic and predictive values for tumor response. In univariate analysis, five SNPs in ERCC2, XPA, MTHFR and ERCC1 were associated with the Dworak score in the CAPOX50 arm. In the overall population, interaction with treatment arm was significant for ERCC2 rs1799787 (pinteraction = 0.05) and XPA rs3176683 (pinteraction = 0.008), suggesting a predictive effect for response to oxaliplatin-based chemoradiotherapy (CRT). All but XPA rs3176683 had a prognostic effect on tumor response. In a multivariate model, interaction remained significant for XPA rs3176683 ([OR 7.33, 95% CI 1.40-38.23], pinteraction = 0.018) and the prognostic effect significant for ERCC2 rs1799787 ([OR 0.55, 95%CI 0.32-0.93], p = 0.027) and ERCC1 rs10412761 ([OR 0.57, 95%CI 0.34-0.98], p = 0.042). Patients with the T/G haplotype of rs1799787 and rs10412761 had a 60% decrease in odds of response (p < 0.001). None of the five SNPs were associated with toxicity, overall and disease-free survival. These data suggest that genetic variation in DNA repair genes influences response to preoperative CRT in LARC and identify patients who benefit from the addition of oxaliplatin to CRT.
Collapse
Affiliation(s)
- Valérie Boige
- Department of Oncologic Medicine, Gustave-Roussy, Villejuif, France.,Université Paris Descartes; Paris Sorbonne Cité INSERM UMR-S775, Paris, France
| | - Caroline Mollevi
- Biometry Unit, Institut du Cancer Montpellier, Université de Montpellier, Montpellier, France.,Institut de Recherche en Cancérologie de Montpellier Inserm U1194, Université de Montpellier, Montpellier, France
| | - Sophie Gourgou
- Biometry Unit, Institut du Cancer Montpellier, Université de Montpellier, Montpellier, France.,Institut de Recherche en Cancérologie de Montpellier Inserm U1194, Université de Montpellier, Montpellier, France
| | - David Azria
- Department of Radiation Oncology, Institut du Cancer Montpellier, Univ Montpellier, Inserm U1194 IRCM, Montpellier, France
| | - Jean-François Seitz
- Department of Digestive Oncology, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Marc Vincent
- Université Paris Descartes; Paris Sorbonne Cité INSERM UMR-S775, Paris, France
| | - Ludovic Bigot
- Inserm U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | | | - Isabelle Miran
- Inserm U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Pierre Gerard
- Department of Radiation Oncology, Centre Antoine Lacassagne, Université Côte d'azur, Nice, France
| | - Pierre Laurent-Puig
- Université Paris Descartes; Paris Sorbonne Cité INSERM UMR-S775, Paris, France
| |
Collapse
|
5
|
Madic J, Jovelet C, Lopez J, André B, Fatien J, Miran I, Honoré A, Mezquita L, Besse B, Lacroix L, Droniou M. Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. Oncotarget 2019; 10:1345. [PMID: 30863495 PMCID: PMC6407683 DOI: 10.18632/oncotarget.26686] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
[This corrects the article DOI: 10.18632/oncotarget.26446.].
Collapse
Affiliation(s)
- Jordan Madic
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| | - Cécile Jovelet
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France
| | - Julien Lopez
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| | - Barbara André
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| | - Jean Fatien
- Ecole Polytechnique, Route de Saclay, Palaiseau, France
| | - Isabelle Miran
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France
| | - Aurélie Honoré
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France
| | - Laura Mezquita
- Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Benjamin Besse
- Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Ludovic Lacroix
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France.,Département de Biologie et Pathologie Médicales, Institut Gustave Roussy, Villejuif, France
| | - Magali Droniou
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| |
Collapse
|
6
|
Madic J, Jovelet C, Lopez J, André B, Fatien J, Miran I, Honoré A, Mezquita L, Besse B, Lacroix L, Droniou M. EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. Oncotarget 2018; 9:37393-37406. [PMID: 30647840 PMCID: PMC6324771 DOI: 10.18632/oncotarget.26446] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 11/26/2018] [Indexed: 12/31/2022] Open
Abstract
Background Detection of EGFR sensitizing and p.T790M and p.C797S resistance mutations is particularly important for non-small cell lung cancer (NSCLC) patient therapy management. Non-invasive blood-based monitoring of these mutations may pave the way to a fine-tuned personalized treatment. Digital PCR has emerged as an extremely sensitive method to detect rare mutations, however its major limitation is the number of hotspots that can be simultaneously differentiated. Methods We developed a 6-color digital PCR assay for the detection and quantification of 19 most prevalent EGFR sensitizing and resistance mutations and evaluated this assay on 82 tumor and plasma samples from NSLC patients. Results Limits of detection (LOD) for the 6-color digital PCR assay were assessed on serial dilutions of DNA standards. We found that the 6-color assay enabled detection of mutant fractions as low as 1 mutant in 1025 wild-type molecules, depending on the mutation targeted, when assayed in a background of 10 000 wild-type DNA copies. EGFR mutant allelic fraction was also measured on tumor and plasma samples by 6-color digital PCR, and displayed a highly significant correlation with next generation sequencing and 3-color digital PCR. Lastly, the 6-color digital PCR assay was performed on several longitudinal plasma samples from four patients and revealed levels of sensitizing and resistance EGFR mutations that reflected well the course of the disease. Conclusion This 6-color Crystal digital PCR assay could represent a robust solution using digital PCR for the monitoring of EGFR mutations.
Collapse
Affiliation(s)
- Jordan Madic
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| | - Cécile Jovelet
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France
| | - Julien Lopez
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| | - Barbara André
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| | - Jean Fatien
- Ecole Polytechnique, Route de Saclay, Palaiseau, France
| | - Isabelle Miran
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France
| | - Aurélie Honoré
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France
| | - Laura Mezquita
- Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Benjamin Besse
- Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France
| | - Ludovic Lacroix
- Plateforme de Génomique, Module de Biopathologie Moléculaire et Centre de Ressources Biologiques, AMMICa, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France.,Département de Biologie et Pathologie Médicales, Institut Gustave Roussy, Villejuif, France
| | - Magali Droniou
- Stilla Technologies, 1 Mail du Professeur Georges Mathé, Villejuif, France
| |
Collapse
|
7
|
Hennig K, Antignac JP, Bichon E, Morvan ML, Miran I, Delaloge S, Feunteun J, Le Bizec B. Steroid hormone profiling in human breast adipose tissue using semi-automated purification and highly sensitive determination of estrogens by GC-APCI-MS/MS. Anal Bioanal Chem 2017; 410:259-275. [PMID: 29147745 DOI: 10.1007/s00216-017-0717-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2017] [Revised: 09/22/2017] [Accepted: 10/18/2017] [Indexed: 01/08/2023]
Abstract
Body mass index is a known breast cancer risk factor due to, among other mechanisms, adipose-derived hormones. We developed a method for steroid hormone profiling in adipose tissue to evaluate healthy tissue around the tumor and define new biomarkers for cancer development. A semi-automated sample preparation method based on gel permeation chromatography and subsequent derivatization with trimethylsilyl (TMS) is presented. Progestagens and androgens were determined by GC-EI-MS/MS (LOQ 0.5 to 10 ng/g lipids). For estrogen measurement, a highly sensitive GC-APCI-MS/MS method was developed to reach the required lower limits of detection (0.05 to 0.1 ng/g lipids in matrix, 100-200 fg on column for pure standards). The combination of the two methods allows the screening of 27 androgens and progestagens and 4 estrogens from a single sample. Good accuracies and repeatabilities were achieved for each compound class at their respective limit of detection. The method was applied to determine steroid hormone profiles in adipose tissue of 51 patients, collected both at proximity and distant to the tumor. Out of the 31 tested steroid hormones, 14 compounds were detected in human samples. Pregnenolone, 17-hydroxypregnenolone, dehydroepiandrosterone (DHEA), and androstendione accounted together for 80% of the observed steroid hormone profiles, whereas the estrogens accounted for only 1%. These profiles did not differ based on sampling location, except for ß-estradiol; steroid hormone conversions from androgens to estrogens that potentially take place in adipose or tumoral tissue might not be detectable due a factor 100 difference in concentration of for example DHEA and ß-estradiol. Graphical Abstract Schematic overview of the determination of steroid hormones and metabolites in adipose tissue in proximity and distal to the tumor.
Collapse
Affiliation(s)
- Kristin Hennig
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), ONIRIS, LUNAM Université, 44307, Nantes, France
| | - Jean Philippe Antignac
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), ONIRIS, LUNAM Université, 44307, Nantes, France.
| | - Emmanuelle Bichon
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), ONIRIS, LUNAM Université, 44307, Nantes, France
| | - Marie-Line Morvan
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), ONIRIS, LUNAM Université, 44307, Nantes, France
| | - Isabelle Miran
- UMR981 INSERM, Gustave Roussy, Paris-Saclay University, 94805, Villejuif, France
| | - Suzette Delaloge
- Breast Cancer Group, Gustave Roussy Cancer Campus, 94805, Villejuif, France
| | - Jean Feunteun
- UMR8200 CNRS, Gustave Roussy, Paris-Saclay University, 94805, Villejuif, France
| | - Bruno Le Bizec
- Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), ONIRIS, LUNAM Université, 44307, Nantes, France
| |
Collapse
|
8
|
Valerie B, Mollevi C, Chaput N, Gourgou S, Azria D, Seitz J, Bigot L, Juzyna B, Miran I, Gérard JP, Laurent-Puig P. Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Boige V, Mollevi C, Chaput N, Gourgou S, Azria D, Seitz JF, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P. Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e15151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15151 Background: We examined whether 133 germline polymorphisms (SNPs) in 15 candidate genes (CSF1R, IL8RA, TLR4, IL10, IL10RA, CTLA4, IL2, IL2RA, TGF b1, ICOS, IL13, IL13RA2, IFNgR, IL15 and IL15RA) would predict clinical outcome in the ACCORD-12 phase III trial which randomly compared neoadjuvant radiotherapy (RT) plus capecitabine (CAP45) with dose-intensified RT plus capecitabine and oxaliplatin (CAPOX50) in T3-4 Nx M0 resectable rectal cancer. Methods: A candidate-gene association study was conducted in 316 patients (n = 161 in the CAPOX50 and n = 155 in the CAP45 arm). The primary end-point was tumor response according to the Dworak score in each arm. Logistic regressions were used to assess univariate/multivariate associations. The Storey and Tibshirani method based on the control of false discovery rate was used ( q-value < 0.10 (adjusted p-value) considered as true discovery). Multivariate models adjusted on treatment arm and T stage were performed to determine prognostic and predictive values of SNPs for tumor response. Results: In univariate analysis, two SNPs in IL2RA (rs11256456: OR = 5.1 [2.38; 11] and rs706781: OR = 4.2 [1.98 ; 8.74]) were significantly associated with the Dworak score in the CAP45 arm, and one in IL2RA the CAPOX50 arm (rs2104286: OR = 0.11 [0.01 ; 0.90]. All were confirmed in the multivariate analysis. A significant haplotypic effect was observed in the CAP-45 arm (p = 0.0001). Interaction was significant for IL2RA rs11256456 ( p= 0.03) and rs706781 ( p= 0.002) and no significant for IL2RA rs2104286 ( p= 0.722), suggesting a predictive deleterious effect the first two ones for response to oxaliplatin-based chemoRT, and a prognostic effect of the third one for response to chemoRT (+/- oxaliplatin). None of the three IL2RA SNPs were correlated with survival in the multivariate analysis. Conclusions: This pharmacogenetic analysis shows that SNPs in IL2RA have a significant association with response to chemoRT with capecitabine in patients with locally advanced rectal cancer. Their predictive effect may identify patients in whom oxaliplatin addition to chemoRT is deleterious.
Collapse
Affiliation(s)
- Valerie Boige
- Service d'Oncologie Digestive, Gustave Roussy, Villejuif, France
| | | | - Nathalie Chaput
- Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS / US 23 INSERM, Gustave Roussy, Villejuif, France
| | - Sophie Gourgou
- Biostatistics Unit, CTD INCa, ICM-Montpellier Cancer Institute, Montpellier, France
| | - David Azria
- Institut Régional du Cancer, Montpellier, France
| | | | - Ludovic Bigot
- Gustave Roussy, Drug Development Department (DITEP); Inserm U981, Villejuif, France
| | | | - Isabelle Miran
- Laboratoire de Recherche Translationnelle, Gustave Roussy, Villejuif, France
| | | | | |
Collapse
|
10
|
Rodriguez C, Suciu V, Poterie A, Lacroix L, Miran I, Boichard A, Delaloge S, Deneuve J, Azoulay S, Mathieu MC, Valent A, Michiels S, Arnedos M, Vielh P. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients. Mol Oncol 2016; 10:1430-1436. [PMID: 27555543 DOI: 10.1016/j.molonc.2016.07.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 06/13/2016] [Accepted: 07/20/2016] [Indexed: 11/16/2022] Open
Abstract
Determining the status of HER2-neu amplification and overexpression in breast cancer is crucial for prognosis but mostly for treatment purposes. Standard techniques include the determination of IHC in combination with in situ hybridization techniques to confirm a HER2-neu amplification in case of IHC2+ using either a core-needle biopsy or a surgical specimen. qPCR has been also demonstrated to be able to determine HER2 status, mostly in core biopsies or in surgical specimens. Fine-needle aspiration is a reliable, quicker and less invasive technique that is widely used for diagnosis of invasive breast cancer. In this study, we assessed the performance of qPCR in invasive breast carcinomas to determine HER2-neu status by using fine-needle aspiration samples and comparing to standard IHC and FISH. From a total of 154 samples from patients who had nodular breast lesions and attended the 1-day-stop clinic at the Gustave Roussy from March 2013 to October 2014, qPCR was able to determine the HER2 status in a mean of 3.7 days (SD 3.1). The overall concordance with standard HER2-testing was very high: 97% (95% CI 0.94 to 0.99); sensitivity was 96% (0.87-1), specificity 98% (0.95-1) and positive and negative predictive values 88% (0.75-1) and 99% (0.98-1), respectively. In conclusion, our study demonstrates that qPCR performed using fine-needle aspiration samples from a primary tumour is a reliable and fast method to determine HER2/neu status in patients with early breast cancer.
Collapse
Affiliation(s)
- Claudia Rodriguez
- Oncologia Medica, Centro Universitario Contra el Cancer, Universidad Autonoma de Nuevo Leon, Mexico
| | - Voichita Suciu
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Audrey Poterie
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, Villejuif, France
| | - Ludovic Lacroix
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France
| | - Isabelle Miran
- Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France
| | - Amélie Boichard
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France
| | - Suzette Delaloge
- Departement de Médecine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Jacqueline Deneuve
- Service des Opérations de Recherche Clinique, Gustave Roussy Cancer Campus, Villejuif, France
| | - Sandy Azoulay
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Marie-Christine Mathieu
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Alexander Valent
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France
| | - Stefan Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, Villejuif, France; INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Monica Arnedos
- Departement de Médecine, Gustave Roussy Cancer Campus, Villejuif, France; INSERM U981 et Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Philippe Vielh
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France.
| |
Collapse
|
11
|
Scherer D, Miran I, Mazouni C, Sarfati B, Bernard M, Adam J, Louvet E, Drusch F, Vielh P, Alhazmi K, Ulrich CM, Delaloge S, Feunteun J. Abstract 4286: Gene expression profiles in adipose tissue of cancer-bearing breasts differ from that of tumor-free breasts. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Adipose tissue - long believed to be no more than an energy storage organ - is metabolically active and consists of a variety of cell types. Adipocytes, fibroblasts and macrophages reside in adipose tissue and may have tumor-promoting properties through the release of cytokines and other growth stimulating molecules. Further, adipose tissue has the capacity of storing pollutants and carcinogens. Breast tumors are embedded in adipose tissue and the direct interface between tumor and adipose tissue in the breast defines a micro-environment potentially fostering tumor initiation and/or progression. The aim of this study was to investigate the transcriptome of adipose tissue from cancer-bearing breasts, localized either close to or distant from the tumor, in addition to comparing it to adipose tissue from tumor-free breasts.
Methods
We collected adipose tissue from n = 33 tumor-bearing breasts (a) close to (< 2cm) and (b) distant from (>5cm) the tumor and from n = 5 tumor-free breasts to investigate gene expression profiles in these three series of tissues. Gene expression was measured from RNA isolated from fresh frozen adipose tissue using Illumina HT12 bead arrays. Quantile normalized expression values were analyzed between (a) and (b) as well as between (a)+(b) and (c) using t-test. Data was filtered by standard variation of 0.95. P-values ≤0.001 were considered significant.
Results
We did not observe any significant differences in gene expression when comparing adipose tissue close to or distant from the tumor. By contrast, expression profiles in adipose tissue of tumor-free breasts clearly differed from that of cancer-bearing breasts. We observed 81 genes significantly differentially expressed between the two groups. Among the overexpressed genes were the previously identified genes MARCO and VSIG4, which were 1.5-fold upregulated in adipose tissue from diseased patients (both p-value = 0.001). Both genes are involved in processes of immunity and inflammation, promoting immune-tolerance in macrophages and T-cells. Other differentially expressed genes also relate to these pathways including CD163, CCL13 and C3. This striking role of inflammatory and immune-modulatory processes was further supported by pathway analyses.
Conclusions
Breast adipose tissues of cancer-bearing breasts show distinct gene expression profiles from that of tumor-free breasts, whereas tumor-distant and tumor-close adipose tissues are similar. However the selected distance of ≤2cm from the tumor may by insufficient to capture the tumor micro-environment. Nevertheless, this rather provocative result raises issues related to the status of breast adipose tissue that may define individually determined cancer fields. Differentially expressed genes are, to a large proportion, involved in immunity-related and inflammatory processes, emphasizing that adipose tissue is an important contributor to one of the hallmarks of cancer.
Citation Format: Dominique Scherer, Isabelle Miran, Chafika Mazouni, Benjamin Sarfati, Marine Bernard, Julien Adam, Emilie Louvet, Francoise Drusch, Philippe Vielh, Khalid Alhazmi, Cornelia M. Ulrich, Suzette Delaloge, Jean Feunteun. Gene expression profiles in adipose tissue of cancer-bearing breasts differ from that of tumor-free breasts. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4286.
Collapse
|
12
|
Boige V, Mollevi C, Azria D, Gourgou S, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P. Association of polymorphisms with tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation: Pharmacogenetic analysis of ACCORD-12/PRODIGE-2 trial. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.3583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Caroline Mollevi
- Institut régional du Cancer de Montpellier (ICM), Montpellier, France
| | - David Azria
- Institut Régional du Cancer, Montpellier, France
| | - Sophie Gourgou
- Biostatistics Unit, CTD INCa, ICM-Montpellier Cancer Institute, Montpellier, France
| | | | | | | | | | - Isabelle Miran
- Laboratoire de recherche translationnelle, Gustave Roussy, Villejuif, France
| | | | | |
Collapse
|
13
|
Leary A, Rajpar S, Mace S, Duvillard P, Rey A, Gouy S, Haie-Meder C, Pautier P, Egile C, Miran I, Lacroix L, Lhomme C. Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple oncogenic pathways. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5514] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Alexandra Leary
- Department of Medicine and INSERM U981, Gustave Roussy, Villejuif, France
| | - Shanna Rajpar
- Department of Medicine, Gustave Roussy, Villejuif, France
| | | | | | | | - Sebastien Gouy
- Department of Surgery, Institut Gustave Roussy, Villejuif, France
| | | | | | | | - Isabelle Miran
- Translational Research, Gustave Roussy, villejuif, France
| | | | | |
Collapse
|
14
|
Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28:2556-64. [PMID: 20385995 DOI: 10.1200/jco.2009.25.2106] [Citation(s) in RCA: 126] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The aim was to investigate whether germline polymorphisms within candidate genes known or suspected to be involved in fluorouracil (FU), oxaliplatin, and irinotecan pathways were associated with toxicity and clinical outcome in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Blood samples from 349 patients included in the Fédération Francophone de Cancérologie Digestive 2000-05 randomized trial, which compared FU plus leucovorin (LV5FU2) followed by FU, leucovorin, and oxaliplatin (FOLFOX) followed by FU, leucovorin, and irinotecan (FOLFIRI; sequential arm) with FOLFOX followed by FOLFIRI (combination arm) in terms of progression-free survival (PFS) and overall survival, were collected. Twenty polymorphisms within the DPD, TS, MTHFR, ERCC1, ERCC2, GSTP1, GSTM1, GSTT1, and UGT1A1 genes were genotyped. RESULTS The ERCC2-K751QC allele was independently associated with an increased risk of FOLFOX-induced grade 3 or 4 hematologic toxicity (P = .01). In the sequential arm, TS-5'UTR3RG and GSTT1 alleles were independently associated with response to LV5FU2 (P = .009) and FOLFOX (P = .01), respectively. The effect of oxaliplatin on tumor response increased with the number of MTHFR-1298C alleles (test for trend, P = .008). The PFS benefit from first-line FOLFOX was restricted to patients with 2R/2R (hazard ratio [HR] = 0.39; 95% CI, 0.23 to 0.68) or 2R/3R (HR = 0.59; 95% CI, 0.42 to 0.82) TS-5'UTR genotypes, respectively. Conversely, patients with the TS-5'UTR 3R/3R genotype did not seem to benefit from the adjunction of oxaliplatin (HR = 0.96; 95% CI, 0.66 to 1.40; trend between the three HRs, P = .006). CONCLUSION A pharmacogenetic approach may be a useful strategy for personalizing and optimizing chemotherapy in mCRC patients and deserves confirmation in additional prospective studies.
Collapse
Affiliation(s)
- Valérie Boige
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Castaing M, Loriot MA, Barrois M, Miran I, Mulot C, Laurent-Puig P, Pignon JP, Ducreux M, Boige V. Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000–05 trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2508 Background: The FFCD 2000–05 randomized trial compared simplified LV5FU2 followed by FOLFOX6 (arm 1) to FOLFOX6 followed by FOLFIRI (arm 2) in the treatment of metastatic colorectal cancer. The aim was predicting the toxicity profile of oxaliplatin after the first line treatment using pharmacogenetic data. Methods: Patients (pts) with available blood samples were compared to the other pts for clinical prognostic factors (chi2 test). A logistic model was computed to test the association between polymorphisms and toxicity in each arm. An interaction test was used to assess a differential effect according to treatment (predictive effect), in order to identify a predictive effect of oxaliplatin. Grade 3–4 hematological and non-hematological toxicities (H-tox and NH-tox) at 4 months and grade 2–4 neurological at 6 months were the endpoints of the study. Thirteen genetic variants in 10 candidate genes were selected for pharmacogenetic analysis: ERCC1_04 (rs3212961), ERCC1_05 (rs11615), ERCC1_06 (rs3212948), ERCC1_24 (rs3212955), ERCC2_02 (rs1799793), ERCC2_03 (rs13181), ERCC2_06 ( rs238406 ), ERCC2_09 (rs1799787), GSTM1 (null/present), GSTT1 (null/present), TS (TSER, Ins/del6bp) and UGT1A1 (rs8175347). Genotyping was performed using Taqman probes, QMPSF and fragment analysis. Results: 327 pts (156/171) out of 410 were included (61 had no blood samples, 16 had less than 2 cycles, 3 had incomplete data on toxicity, 3 had insufficient DNA). No difference was found between included and excluded pts in the analysis for gender, age, OMS, number of metastatic organs and adjuvant chemotherapy. Pts received similar 5FU doses in both arms. Number of patients with at least one toxicity in arms 1/2 were as followed: 5/54 grade 3–4 H-tox, 28/47 grade 3–4 NH-tox, and 0/103 grade 2–4 neurological. The genotype CC of ERCC2_02 correlated with higher NH-tox at 4 months in arm 2 (p=0.0008, OR=0.31, 95%CI=[0.15–0.62] versus p=0.87, OR=0.93, CI=[0.39–2.21] in arm 1) compared to genotypes CT and TT, with borderline interaction (p=0.05). Conclusions: These preliminary results on early toxicity in first-line are in favour of an effect of ERCC2_02 on NH-tox of FOLFOX6 and a predictive effect on NH-tox of oxaliplatin. [Table: see text]
Collapse
Affiliation(s)
- M. Castaing
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - M. A. Loriot
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - M. Barrois
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - I. Miran
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - C. Mulot
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - P. Laurent-Puig
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - J. P. Pignon
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - M. Ducreux
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| | - V. Boige
- Institut Gustave-Roussy, Villejuif, France; INSERM U775, Paris, France
| |
Collapse
|
16
|
Andre F, Sabourin JC, Assi H, Miran I, Podolsky D, Spielmann M, Zitvogel L. Targeting Toll like receptor 3 by double stranded RNA in breast cancer: Results from in vitro studies and randomized trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Andre
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| | - J. C. Sabourin
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| | - H. Assi
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| | - I. Miran
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| | - D. Podolsky
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| | - M. Spielmann
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| | - L. Zitvogel
- Institut Gustave Roussy, Villejuif, France; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
17
|
Janneau JL, Maldonado-Estrada J, Tachdjian G, Miran I, Motté N, Saulnier P, Sabourin JC, Coté JF, Simon B, Frydman R, Chaouat G, Bellet D. Transcriptional expression of genes involved in cell invasion and migration by normal and tumoral trophoblast cells. J Clin Endocrinol Metab 2002; 87:5336-9. [PMID: 12414911 DOI: 10.1210/jc.2002-021093] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Once initiated, invasion of trophoblast cells must be tightly regulated, particularly in early pregnancy. The mechanisms necessary for the invasion and migration of trophoblast cells are thought to be related to those involved in the invasive and metastatic properties of cancer cells. Quantitative PCR was used to measure, in trophoblast cells, the transcriptional expression profiles of four genes, INSL4, BRMS1, KiSS-1 and KiSS-1R, reported to be implicated in tumor invasion and metastasis. Laser capture microdissection and purification of trophoblast cells demonstrate that, as already known for INSL4, BRMS1, KiSS-1 and KiSS-1R are expressed by the trophoblast subset of placental tissues. Expression profiles of these genes studied in early placentas (7-9 weeks, n=55) and term placentas (n=11) showed that expression levels of BRMS1 are higher in term than in early placentas, while expression levels of KiSS-1R are higher in early than in term placentas. Low levels of expression of BRMS1 were observed in normal pregnancies, in molar pregnancies and in choriocarcinoma cell lines BeWo, JAR and JEG3 while, in striking contrast, the expression levels of INSL4, KiSS-1 and Kiss-1R were increased in both early placentas and molar pregnancies and were reduced in choriocarcinoma cells. These transcriptional expression profiles are in favor of a predominant role of INSL4, KiSS-1 and KiSS-1R in the control of the invasive and migratory properties of trophoblast cells.
Collapse
Affiliation(s)
- Jean-Louis Janneau
- Laboratoire d'Immunologie des Tumeurs ESA 8067 CNRS, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, Université René Descartes-Paris 5, Paris
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|